FDA has granted orphan drug designation to FS2 (kynurenic acid) for the investigational treatment of idiopathic pulmonary ...
Nerandomilast, a PDE4 inhibitor, has shown significant efficacy in progressive pulmonary fibrosis (PPF), offering an ...
CNW/ - BirchBioMed Inc., a leading clinical stage biopharmaceutical company, expert in the development of products for ...
Nerandomilast, a PDE4B inhibitor, is a new treatment option for IPF, showing better tolerability than nintedanib and ...
CHICAGO, June 5, 2025 /PRNewswire/ -- The Pulmonary Fibrosis Foundation (PFF)'s, the nation's leading pulmonary fibrosis (PF) research, education, and advocacy organization, invites people living with ...
News-Medical.Net on MSN
Cystic fibrosis patients on triple-drug therapy can safely reduce daily lung treatments
A new multi-site study led by researchers at CU Anschutz shows that people with cystic fibrosis (CF) who start the ...
Researchers at Tulane University have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people ...
MILAN ― Numerous unresolved questions surround progressive pulmonary fibrosis (PPF) treatment, according to Elisabeth Bendstrup, MD, PhD, a researcher and clinical professor in the Department of ...
Cystic fibrosis (CF) and pulmonary fibrosis (PF) are two chronic conditions that damage the lungs. Treatment for both aims to improve breathing, manage symptoms, and prevent further lung damage. Your ...
The MarketWatch News Department was not involved in the creation of this content. CHICAGO, June 5, 2025 /PRNewswire/ -- The Pulmonary Fibrosis Foundation (PFF)'s, the nation's leading pulmonary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback